Starting GLP-1 Now vs Waiting: The Cost of Delay

Introduction

The decision to start a GLP-1 isn’t urgent in the same way that treating a heart attack is urgent. Patients can wait months or years to decide. Many do.

The cost of waiting isn’t always obvious, but it’s real. Metabolic diseases progress quietly. Cardiovascular risk accumulates. Muscle and joint problems compound. The next generation of obesity drugs may take years to reach market, and the better drug you’re waiting for may not be substantially better than what’s available today.

This guide walks through what waiting actually costs, framed by trial data on what GLP-1s do to disease trajectories over time.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does Delay Cost in Cardiovascular Terms?

The SELECT trial gives the clearest answer. Semaglutide 2.4 mg reduced major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke) by 20% over 3.3 years in 17,604 adults with overweight or obesity plus established CVD. The number needed to treat to prevent one event was around 65 over the trial period.

Quick Answer: SELECT (Lincoff et al. 2023 NEJM) showed semaglutide reduced major cardiovascular events by 20% over 3.3 years; each year of delay loses potential CV protection

For patients without established CVD, the absolute risk per year is lower but the relative benefit is similar. Patients with obesity, age 50+, or other CV risk factors carry meaningful annual risk of cardiovascular events. Each year on effective treatment reduces that annual risk.

A patient who delays starting a GLP-1 by 2 years effectively forgoes 2 years of potential 20% relative risk reduction. For some patients that’s a few percentage points of absolute risk. For high-risk patients with existing CVD, it can be a meaningful difference.

What Does Delay Cost in Kidney Terms?

The FLOW trial showed semaglutide reduced kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease over 3.4 years. Kidney function in diabetic CKD typically declines over years; faster decline correlates with earlier dialysis, transplant, or kidney-related death.

Once nephrons are lost they can’t be regenerated. Delaying treatment that slows nephron loss has consequences that aren’t recoverable. Patients with stage 2 or 3 diabetic CKD have a particular window where intervention can preserve substantial future function.

What Does Delay Cost in Diabetes Terms?

Type 2 diabetes is a progressive disease. Beta cells in the pancreas that produce insulin gradually fail under the long-term metabolic stress of hyperglycemia and insulin resistance. Once beta-cell function is severely diminished, achieving good glycemic control requires more medication and eventually insulin.

Earlier intervention in type 2 diabetes preserves beta-cell function longer. The DPP (Diabetes Prevention Program) showed that lifestyle intervention reduced progression from prediabetes to diabetes by 58% in high-risk adults. Patients who progress to diabetes years later have lower baseline beta-cell function than those who never progress.

GLP-1s in particular have favorable effects on beta-cell function over time. Starting earlier in the diabetes trajectory likely preserves more pancreatic function than starting later.

What Does Delay Cost in Weight Maintenance?

This is less obvious but documented. Patients who carry obesity for longer accumulate physiological changes that make weight loss harder over time. Adipose tissue inflammation increases. Insulin resistance worsens. Set-point regulation shifts upward. Sleep apnea develops or worsens. Joint problems progress.

Patients treated earlier (at lower BMIs and shorter durations of obesity) tend to achieve better outcomes from any weight loss intervention, including bariatric surgery and GLP-1 medications. The same medication dose produces somewhat more weight loss in patients with shorter obesity duration than in patients with decades of accumulated metabolic adaptation.

What Does Delay Cost in Joint and Orthopedic Terms?

Knee osteoarthritis is a strong example. The IDEA trial (Messier 2013 JAMA) showed that combined diet and exercise produced 11% weight loss and reduced knee pain by 51%. STEP 9 (Bliddal et al. 2024 NEJM) showed semaglutide reduced knee pain in patients with obesity and knee osteoarthritis.

Cartilage damage in knees doesn’t reverse. Once joint surfaces deteriorate, joint replacement becomes the eventual answer. Delaying weight loss treatment allows joint damage to progress under continued load. Patients who lose weight earlier preserve more joint function over time.

The same logic applies to spinal disc disease, hip osteoarthritis, and other obesity-aggravated orthopedic conditions.

What About Waiting for Better Drugs?

Retatrutide produced 24.2% weight loss in phase 2 (Jastreboff et al. 2023 NEJM), compared to tirzepatide’s 20.9% in SURMOUNT-1. The triple agonist’s edge is real but modest. Phase 3 trials are running. Likely FDA submission is late 2026 or 2027. Likely approval, if it comes, is late 2027 or 2028.

Other drugs in development include oral tirzepatide, CagriSema, survodutide, and several earlier-stage candidates. None will be available before late 2027 at the earliest for most patients.

Waiting 2 to 4 years for marginally better drugs is rarely the best move. Two years of effective treatment now beats two years of no treatment followed by switching to a slightly better drug later. The cardiovascular, kidney, metabolic, and orthopedic benefits compound during the years of waiting.

For specific patients (those with extreme obesity who might benefit substantially from retatrutide’s stronger effect, or those who’ve already failed current options), waiting may make sense. For most patients, starting now and switching later if needed is the better approach.

Key Takeaway: Type 2 diabetes typically progresses if untreated; earlier intervention preserves beta-cell function longer

What Does Waiting Cost Financially?

Compounded GLP-1 through telehealth platforms like TrimRx typically runs $200 to $500/month. Annual cost: $2,400 to $6,000. Two years of treatment: $4,800 to $12,000.

The financial cost of delay is what you save in those years. But weight gain during waiting often means starting later at a higher BMI, requiring longer treatment to reach goal, and accumulating other costs (medical visits for obesity-related conditions, lost productivity from fatigue and joint pain, eventual procedures like joint replacement or bariatric surgery).

The financial calculation is rarely as simple as “save money by waiting.” More often the costs shift from one category (medication) to another (medical procedures, lost wages, comorbidity treatment).

What Does the Medical History Say About Delaying Obesity Treatment?

For decades, the standard approach to obesity was lifestyle counseling alone, with surgery reserved for severe cases. Patients spent years cycling through diets, gaining and losing the same weight, accumulating health consequences. Effective medication didn’t exist for most of that history.

The arrival of GLP-1s changed what’s possible. Patients can now achieve weight loss outcomes previously only seen with surgery, without surgical risk. The question isn’t whether to treat obesity, it’s how aggressively and how early.

Most obesity medicine clinicians now favor earlier intervention. Waiting for a different time or a better drug means accepting the well-documented downstream costs of untreated obesity in the meantime.

Who Should Consider Waiting?

Some patients are reasonable candidates for delay. Patients without comorbidities, with stable weight, who are actively working on lifestyle changes and seeing results without medication, might reasonably postpone medication if their trajectory is good.

Patients in their early 20s with mild overweight who are still figuring out their long-term metabolic trajectory may not need pharmacologic intervention yet. Patients planning pregnancy within the next year shouldn’t start GLP-1s due to contraindication.

Patients with specific contraindications (history of medullary thyroid carcinoma, MEN2 syndrome) shouldn’t start GLP-1s and need different treatment options.

Who Shouldn’t Wait?

Patients with established cardiovascular disease, type 2 diabetes, chronic kidney disease, moderate-to-severe sleep apnea, or significant obesity-aggravated joint disease have evidence-backed reasons to treat now. The trial data on outcome reductions is strongest for these populations and the absolute benefit per year is highest.

Patients with BMI 40+ (class III obesity) who are weighing bariatric surgery should consider that current GLP-1s, especially tirzepatide, may now produce weight loss approaching surgical outcomes with substantially less risk.

TrimRx’s free assessment quiz screens eligibility for compounded semaglutide and tirzepatide and connects qualifying patients with a personalized treatment plan.

Bottom line: Retatrutide and other next-gen drugs are 2 to 4 years from FDA approval; waiting is a substantial timeline

FAQ

How Fast Do GLP-1 Benefits Accumulate?

Weight loss begins within weeks. Cardiovascular and metabolic benefits build over months to years. SELECT showed CV benefit emerging within the first year of treatment and continuing throughout the 3.3-year trial.

If I Start Now, Am I Locked In?

No. GLP-1s can be stopped at any time. Most patients regain weight after stopping, so long-term use is typical, but the decision to start isn’t a permanent commitment.

What If My Insurance Starts Covering GLP-1s Next Year?

You can switch from cash-pay compounded to insurance-covered brand drugs if and when coverage opens. Treatment continuity is preserved through the switch.

Will the Price Come Down If I Wait?

Possibly, but slowly. Compounded GLP-1 pricing has been falling. Brand drug pricing has dropped modestly with direct cash programs (LillyDirect, NovoCare). Major price drops typically come with generic availability, which is years away.

Should I Wait Until I’ve Tried More Lifestyle Changes?

For patients with BMI under 30 and no comorbidities, more lifestyle effort first is reasonable. For patients with BMI 30+ or with obesity-related comorbidities, the outcome data favors starting medication alongside lifestyle work rather than waiting indefinitely.

Could the New Drugs Be That Much Better?

Probably not substantially better for most patients. Retatrutide in phase 2 produced 3 to 4 percentage points more weight loss than tirzepatide. Meaningful but not transformative. The bigger gains in this drug class have likely already been captured by semaglutide and tirzepatide.

When Is the Right Time to Start?

When you’ve decided that the risks and burdens of treatment are smaller than the costs of continuing without treatment. For most patients with obesity and any obesity-related comorbidity, that calculation favors starting sooner.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.